BEGIN:VCALENDAR
VERSION:2.0
PRODID:-//AssetMemo//Readout calendar//EN
CALSCALE:GREGORIAN
METHOD:PUBLISH
X-WR-CALNAME:Alemtuzumab readouts · AssetMemo
X-WR-CALDESC:Upcoming readouts of Alemtuzumab\, from ClinicalTrials.gov est
 imates.
REFRESH-INTERVAL;VALUE=DURATION:PT12H
X-PUBLISHED-TTL:PT12H
BEGIN:VEVENT
UID:NCT01962415-6149@assetmemo.bio
DTSTAMP:20261121T004952Z
DTSTART;VALUE=DATE:20261130
DTEND;VALUE=DATE:20261201
SUMMARY:Alemtuzumab: Phase 2 readout est. (NCT01962415)
DESCRIPTION:Alemtuzumab\, phase 2.\nStudy: Reduced Intensity Conditioning f
 or Non-Malignant Disorders Undergoing UCBT\, BMT or PBSCT\nEstimated prima
 ry completion: November 2026. This is a ClinicalTrials.gov estimate\, not 
 a confirmed readout date\, and it can move.\nDrug page: https://assetmemo.
 bio/drug/alemtuzumab#upcoming-events\nRegistry record: https://clinicaltri
 als.gov/study/NCT01962415
URL:https://assetmemo.bio/drug/alemtuzumab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT04018937-6149@assetmemo.bio
DTSTAMP:20261121T004952Z
DTSTART;VALUE=DATE:20261130
DTEND;VALUE=DATE:20261201
SUMMARY:Alemtuzumab: Phase 2 readout est. (NCT04018937)
DESCRIPTION:Alemtuzumab\, phase 2.\nStudy: Early Human Leukocyte Antigen (H
 LA) Matched Sibling Hematopoietic Stem Cell Transplantation\nEstimated pri
 mary completion: November 2026. This is a ClinicalTrials.gov estimate\, no
 t a confirmed readout date\, and it can move.\nDrug page: https://assetmem
 o.bio/drug/alemtuzumab#upcoming-events\nRegistry record: https://clinicalt
 rials.gov/study/NCT04018937
URL:https://assetmemo.bio/drug/alemtuzumab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT00692939-6149@assetmemo.bio
DTSTAMP:20261121T004952Z
DTSTART;VALUE=DATE:20261231
DTEND;VALUE=DATE:20270101
SUMMARY:Alemtuzumab: Phase 1/2 readout est. (NCT00692939)
DESCRIPTION:Alemtuzumab\, phase 1/2.\nStudy: Autologous Stem Cell Transplan
 tation for Crohn's Disease\nEstimated primary completion: December 2026. T
 his is a ClinicalTrials.gov estimate\, not a confirmed readout date\, and 
 it can move.\nDrug page: https://assetmemo.bio/drug/alemtuzumab#upcoming-e
 vents\nRegistry record: https://clinicaltrials.gov/study/NCT00692939
URL:https://assetmemo.bio/drug/alemtuzumab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT00920972-6149@assetmemo.bio
DTSTAMP:20261121T004952Z
DTSTART;VALUE=DATE:20261231
DTEND;VALUE=DATE:20270101
SUMMARY:Alemtuzumab: Phase 1/2 readout est. (NCT00920972)
DESCRIPTION:Alemtuzumab\, phase 1/2.\nStudy: Campath/Fludarabine/Melphalan 
 Transplant Conditioning for Non-Malignant Diseases\nEstimated primary comp
 letion: December 2026. This is a ClinicalTrials.gov estimate\, not a confi
 rmed readout date\, and it can move.\nDrug page: https://assetmemo.bio/dru
 g/alemtuzumab#upcoming-events\nRegistry record: https://clinicaltrials.gov
 /study/NCT00920972
URL:https://assetmemo.bio/drug/alemtuzumab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT01659606-6149@assetmemo.bio
DTSTAMP:20261121T004952Z
DTSTART;VALUE=DATE:20261231
DTEND;VALUE=DATE:20270101
SUMMARY:Alemtuzumab: Phase 2 readout est. (NCT01659606)
DESCRIPTION:Alemtuzumab\, phase 2.\nStudy: Radiation- and Alkylator-free Bo
 ne Marrow Transplantation Regimen for Patients With Dyskeratosis Congenita
 \nEstimated primary completion: December 2026. This is a ClinicalTrials.go
 v estimate\, not a confirmed readout date\, and it can move.\nDrug page: h
 ttps://assetmemo.bio/drug/alemtuzumab#upcoming-events\nRegistry record: ht
 tps://clinicaltrials.gov/study/NCT01659606
URL:https://assetmemo.bio/drug/alemtuzumab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT05384756-6149@assetmemo.bio
DTSTAMP:20261121T004952Z
DTSTART;VALUE=DATE:20261201
DTEND;VALUE=DATE:20261202
SUMMARY:Alemtuzumab: Phase 1 readout est. (NCT05384756)
DESCRIPTION:Alemtuzumab\, phase 1.\nStudy: TMLI and Alemtuzumab for Treatme
 nt of Sickle Cell Disease\nEstimated primary completion: 1 December 2026. 
 This is a ClinicalTrials.gov estimate\, not a confirmed readout date\, and
  it can move.\nDrug page: https://assetmemo.bio/drug/alemtuzumab#upcoming-
 events\nRegistry record: https://clinicaltrials.gov/study/NCT05384756
URL:https://assetmemo.bio/drug/alemtuzumab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT03579875-6149@assetmemo.bio
DTSTAMP:20261121T004952Z
DTSTART;VALUE=DATE:20270101
DTEND;VALUE=DATE:20270102
SUMMARY:Alemtuzumab: Phase 2 readout est. (NCT03579875)
DESCRIPTION:Alemtuzumab\, phase 2.\nStudy: Alpha/Beta TCD HCT in Patients W
 ith Inherited BMF Disorders\nEstimated primary completion: 1 January 2027.
  This is a ClinicalTrials.gov estimate\, not a confirmed readout date\, an
 d it can move.\nDrug page: https://assetmemo.bio/drug/alemtuzumab#upcoming
 -events\nRegistry record: https://clinicaltrials.gov/study/NCT03579875
URL:https://assetmemo.bio/drug/alemtuzumab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06959771-6149@assetmemo.bio
DTSTAMP:20261121T004952Z
DTSTART;VALUE=DATE:20271028
DTEND;VALUE=DATE:20271029
SUMMARY:Alemtuzumab: Phase 1/2 readout est. (NCT06959771)
DESCRIPTION:Alemtuzumab\, phase 1/2.\nStudy: Base Editing Hematopoietic Ste
 m Cell and T Cell Gene Therapy for CD40L-HyperIgM Syndrome: Single Patient
  Study\nEstimated primary completion: 28 October 2027. This is a ClinicalT
 rials.gov estimate\, not a confirmed readout date\, and it can move.\nDrug
  page: https://assetmemo.bio/drug/alemtuzumab#upcoming-events\nRegistry re
 cord: https://clinicaltrials.gov/study/NCT06959771
URL:https://assetmemo.bio/drug/alemtuzumab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT03500731-6149@assetmemo.bio
DTSTAMP:20261121T004952Z
DTSTART;VALUE=DATE:20271231
DTEND;VALUE=DATE:20280101
SUMMARY:Alemtuzumab: Phase 1/2 readout est. (NCT03500731)
DESCRIPTION:Alemtuzumab\, phase 1/2.\nStudy: Lung and Bone Marrow Transplan
 tation for Lung and Bone Marrow Failure\nEstimated primary completion: Dec
 ember 2027. This is a ClinicalTrials.gov estimate\, not a confirmed readou
 t date\, and it can move.\nDrug page: https://assetmemo.bio/drug/alemtuzum
 ab#upcoming-events\nRegistry record: https://clinicaltrials.gov/study/NCT0
 3500731
URL:https://assetmemo.bio/drug/alemtuzumab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT02629120-6149@assetmemo.bio
DTSTAMP:20261121T004952Z
DTSTART;VALUE=DATE:20271230
DTEND;VALUE=DATE:20271231
SUMMARY:Alemtuzumab: Phase 1/2 readout est. (NCT02629120)
DESCRIPTION:Alemtuzumab\, phase 1/2.\nStudy: High Dose Peripheral Blood Ste
 m Cell Transplantation With Post Transplant Cyclophosphamide for Patients 
 With Chronic Granulomatous Disease\nEstimated primary completion: 30 Decem
 ber 2027. This is a ClinicalTrials.gov estimate\, not a confirmed readout 
 date\, and it can move.\nDrug page: https://assetmemo.bio/drug/alemtuzumab
 #upcoming-events\nRegistry record: https://clinicaltrials.gov/study/NCT026
 29120
URL:https://assetmemo.bio/drug/alemtuzumab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT04232085-6149@assetmemo.bio
DTSTAMP:20261121T004952Z
DTSTART;VALUE=DATE:20271231
DTEND;VALUE=DATE:20280101
SUMMARY:Alemtuzumab: Phase 2 readout est. (NCT04232085)
DESCRIPTION:Alemtuzumab\, phase 2.\nStudy: Regenerative Medicine to Restore
  Hematopoiesis and Immune Function in Immunodeficiencies and Inherited Bon
 e Marrow Failures\nEstimated primary completion: 31 December 2027. This is
  a ClinicalTrials.gov estimate\, not a confirmed readout date\, and it can
  move.\nDrug page: https://assetmemo.bio/drug/alemtuzumab#upcoming-events\
 nRegistry record: https://clinicaltrials.gov/study/NCT04232085
URL:https://assetmemo.bio/drug/alemtuzumab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06084780-6149@assetmemo.bio
DTSTAMP:20261121T004952Z
DTSTART;VALUE=DATE:20271231
DTEND;VALUE=DATE:20280101
SUMMARY:Alemtuzumab: Phase 2 readout est. (NCT06084780)
DESCRIPTION:Alemtuzumab\, phase 2.\nStudy: Intestinal & Multivisceral Trans
 plantation for Unresectable Mucinous Carcinoma Peritonei (TRANSCAPE)\nEsti
 mated primary completion: 31 December 2027. This is a ClinicalTrials.gov e
 stimate\, not a confirmed readout date\, and it can move.\nDrug page: http
 s://assetmemo.bio/drug/alemtuzumab#upcoming-events\nRegistry record: https
 ://clinicaltrials.gov/study/NCT06084780
URL:https://assetmemo.bio/drug/alemtuzumab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT03214354-6149@assetmemo.bio
DTSTAMP:20261121T004952Z
DTSTART;VALUE=DATE:20280731
DTEND;VALUE=DATE:20280801
SUMMARY:Alemtuzumab: Phase 2 readout est. (NCT03214354)
DESCRIPTION:Alemtuzumab\, phase 2.\nStudy: Nonmyeloablative Stem Cell Trans
 plant in Children With Sickle Cell Disease and a Major ABO-Incompatible Ma
 tched Sibling Donor\nEstimated primary completion: July 2028. This is a Cl
 inicalTrials.gov estimate\, not a confirmed readout date\, and it can move
 .\nDrug page: https://assetmemo.bio/drug/alemtuzumab#upcoming-events\nRegi
 stry record: https://clinicaltrials.gov/study/NCT03214354
URL:https://assetmemo.bio/drug/alemtuzumab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT03653338-6149@assetmemo.bio
DTSTAMP:20261121T004952Z
DTSTART;VALUE=DATE:20280801
DTEND;VALUE=DATE:20280802
SUMMARY:Alemtuzumab: Phase 1/2 readout est. (NCT03653338)
DESCRIPTION:Alemtuzumab\, phase 1/2.\nStudy: T-Cell Depleted Alternative Do
 nor Bone Marrow Transplant for Sickle Cell Disease (SCD) and Other Anemias
 \nEstimated primary completion: 1 August 2028. This is a ClinicalTrials.go
 v estimate\, not a confirmed readout date\, and it can move.\nDrug page: h
 ttps://assetmemo.bio/drug/alemtuzumab#upcoming-events\nRegistry record: ht
 tps://clinicaltrials.gov/study/NCT03653338
URL:https://assetmemo.bio/drug/alemtuzumab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT03630211-6149@assetmemo.bio
DTSTAMP:20261121T004952Z
DTSTART;VALUE=DATE:20280801
DTEND;VALUE=DATE:20280802
SUMMARY:Alemtuzumab: Phase 2 readout est. (NCT03630211)
DESCRIPTION:Alemtuzumab\, phase 2.\nStudy: Autologous Stem Cell Transplanta
 tion in Patients With Systemic Sclerosis\nEstimated primary completion: 1 
 August 2028. This is a ClinicalTrials.gov estimate\, not a confirmed reado
 ut date\, and it can move.\nDrug page: https://assetmemo.bio/drug/alemtuzu
 mab#upcoming-events\nRegistry record: https://clinicaltrials.gov/study/NCT
 03630211
URL:https://assetmemo.bio/drug/alemtuzumab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT05501756-6149@assetmemo.bio
DTSTAMP:20261121T004952Z
DTSTART;VALUE=DATE:20280831
DTEND;VALUE=DATE:20280901
SUMMARY:Alemtuzumab: Phase 2 readout est. (NCT05501756)
DESCRIPTION:Alemtuzumab\, phase 2.\nStudy: Precision Alemtuzumab Dosing for
  Allogeneic Hematopoietic Cell Transplantation\nEstimated primary completi
 on: 31 August 2028. This is a ClinicalTrials.gov estimate\, not a confirme
 d readout date\, and it can move.\nDrug page: https://assetmemo.bio/drug/a
 lemtuzumab#upcoming-events\nRegistry record: https://clinicaltrials.gov/st
 udy/NCT05501756
URL:https://assetmemo.bio/drug/alemtuzumab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT01499888-6149@assetmemo.bio
DTSTAMP:20261121T004952Z
DTSTART;VALUE=DATE:20280923
DTEND;VALUE=DATE:20280924
SUMMARY:Alemtuzumab: Phase 1/2 readout est. (NCT01499888)
DESCRIPTION:Alemtuzumab\, phase 1/2.\nStudy: Ph I/II Study of Allogeneic SC
 T for Clinically Aggressive Sickle Cell Disease (SCD)\nEstimated primary c
 ompletion: 23 September 2028. This is a ClinicalTrials.gov estimate\, not 
 a confirmed readout date\, and it can move.\nDrug page: https://assetmemo.
 bio/drug/alemtuzumab#upcoming-events\nRegistry record: https://clinicaltri
 als.gov/study/NCT01499888
URL:https://assetmemo.bio/drug/alemtuzumab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT04339777-6149@assetmemo.bio
DTSTAMP:20261121T004952Z
DTSTART;VALUE=DATE:20281001
DTEND;VALUE=DATE:20281002
SUMMARY:Alemtuzumab: Phase 2 readout est. (NCT04339777)
DESCRIPTION:Alemtuzumab\, phase 2.\nStudy: Allogeneic Hematopoietic Stem Ce
 ll Transplant for Patients With Inborn Errors of Immunity\nEstimated prima
 ry completion: 1 October 2028. This is a ClinicalTrials.gov estimate\, not
  a confirmed readout date\, and it can move.\nDrug page: https://assetmemo
 .bio/drug/alemtuzumab#upcoming-events\nRegistry record: https://clinicaltr
 ials.gov/study/NCT04339777
URL:https://assetmemo.bio/drug/alemtuzumab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07015684-6149@assetmemo.bio
DTSTAMP:20261121T004952Z
DTSTART;VALUE=DATE:20300312
DTEND;VALUE=DATE:20300313
SUMMARY:Alemtuzumab: Phase 1 readout est. (NCT07015684)
DESCRIPTION:Alemtuzumab\, phase 1.\nStudy: 131I-apamistamab-based Condition
 ing for Hematopoietic Stem Cell Transplant (HSCT) in Advanced Sickle Cell 
 Disease (SCD)\nEstimated primary completion: 12 March 2030. This is a Clin
 icalTrials.gov estimate\, not a confirmed readout date\, and it can move.\
 nDrug page: https://assetmemo.bio/drug/alemtuzumab#upcoming-events\nRegist
 ry record: https://clinicaltrials.gov/study/NCT07015684
URL:https://assetmemo.bio/drug/alemtuzumab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06872333-6149@assetmemo.bio
DTSTAMP:20261121T004952Z
DTSTART;VALUE=DATE:20300601
DTEND;VALUE=DATE:20300602
SUMMARY:Alemtuzumab: Phase 2 readout est. (NCT06872333)
DESCRIPTION:Alemtuzumab\, phase 2.\nStudy: Allo HSCT for High Risk Hemoglob
 inopathies\nEstimated primary completion: 1 June 2030. This is a ClinicalT
 rials.gov estimate\, not a confirmed readout date\, and it can move.\nDrug
  page: https://assetmemo.bio/drug/alemtuzumab#upcoming-events\nRegistry re
 cord: https://clinicaltrials.gov/study/NCT06872333
URL:https://assetmemo.bio/drug/alemtuzumab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT03587272-6149@assetmemo.bio
DTSTAMP:20261121T004952Z
DTSTART;VALUE=DATE:20301130
DTEND;VALUE=DATE:20301201
SUMMARY:Alemtuzumab: Phase 2 readout est. (NCT03587272)
DESCRIPTION:Alemtuzumab\, phase 2.\nStudy: Minimizing Toxicity in HLA-ident
 ical Sibling Donor Transplantation for Children With Sickle Cell Disease\n
 Estimated primary completion: November 2030. This is a ClinicalTrials.gov 
 estimate\, not a confirmed readout date\, and it can move.\nDrug page: htt
 ps://assetmemo.bio/drug/alemtuzumab#upcoming-events\nRegistry record: http
 s://clinicaltrials.gov/study/NCT03587272
URL:https://assetmemo.bio/drug/alemtuzumab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07599176-6149@assetmemo.bio
DTSTAMP:20261121T004952Z
DTSTART;VALUE=DATE:20320630
DTEND;VALUE=DATE:20320701
SUMMARY:Alemtuzumab: Phase 1/2 readout est. (NCT07599176)
DESCRIPTION:Alemtuzumab\, phase 1/2.\nStudy: Partial Stem Cell Transplant f
 or Sickle Cell Disease From Matched Donors\nEstimated primary completion: 
 30 June 2032. This is a ClinicalTrials.gov estimate\, not a confirmed read
 out date\, and it can move.\nDrug page: https://assetmemo.bio/drug/alemtuz
 umab#upcoming-events\nRegistry record: https://clinicaltrials.gov/study/NC
 T07599176
URL:https://assetmemo.bio/drug/alemtuzumab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT05463133-6149@assetmemo.bio
DTSTAMP:20261121T004952Z
DTSTART;VALUE=DATE:20321231
DTEND;VALUE=DATE:20330101
SUMMARY:Alemtuzumab: Phase 1/2 readout est. (NCT05463133)
DESCRIPTION:Alemtuzumab\, phase 1/2.\nStudy: Allogeneic Hematopoietic Stem 
 Cell Transplantation for Chronic Granulomatous Disease (CGD) With an Alemt
 uzumab\, Busulfan and TBI-based Conditioning Regimen Combined With Cytokin
 e (IL-6\, +/- IFN-gamma) Antagonists\nEstimated primary completion: 31 Dec
 ember 2032. This is a ClinicalTrials.gov estimate\, not a confirmed readou
 t date\, and it can move.\nDrug page: https://assetmemo.bio/drug/alemtuzum
 ab#upcoming-events\nRegistry record: https://clinicaltrials.gov/study/NCT0
 5463133
URL:https://assetmemo.bio/drug/alemtuzumab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06325709-6149@assetmemo.bio
DTSTAMP:20261121T004952Z
DTSTART;VALUE=DATE:20321231
DTEND;VALUE=DATE:20330101
SUMMARY:Alemtuzumab: Phase 1/2 readout est. (NCT06325709)
DESCRIPTION:Alemtuzumab\, phase 1/2.\nStudy: Base Editing for Mutation Repa
 ir in Hematopoietic Stem & Progenitor Cells for X-Linked Chronic Granuloma
 tous Disease\nEstimated primary completion: 31 December 2032. This is a Cl
 inicalTrials.gov estimate\, not a confirmed readout date\, and it can move
 .\nDrug page: https://assetmemo.bio/drug/alemtuzumab#upcoming-events\nRegi
 stry record: https://clinicaltrials.gov/study/NCT06325709
URL:https://assetmemo.bio/drug/alemtuzumab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT01306019-6149@assetmemo.bio
DTSTAMP:20261121T004952Z
DTSTART;VALUE=DATE:20321231
DTEND;VALUE=DATE:20330101
SUMMARY:Alemtuzumab: Phase 1/2 readout est. (NCT01306019)
DESCRIPTION:Alemtuzumab\, phase 1/2.\nStudy: Lentiviral Gene Transfer for T
 reatment of Children Older Than Two Years of Age With X-Linked Severe Comb
 ined Immunodeficiency (XSCID)\nEstimated primary completion: 31 December 2
 032. This is a ClinicalTrials.gov estimate\, not a confirmed readout date\
 , and it can move.\nDrug page: https://assetmemo.bio/drug/alemtuzumab#upco
 ming-events\nRegistry record: https://clinicaltrials.gov/study/NCT01306019
URL:https://assetmemo.bio/drug/alemtuzumab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT03910452-6149@assetmemo.bio
DTSTAMP:20261121T004952Z
DTSTART;VALUE=DATE:20340615
DTEND;VALUE=DATE:20340616
SUMMARY:Alemtuzumab: Phase 1 readout est. (NCT03910452)
DESCRIPTION:Alemtuzumab\, phase 1.\nStudy: Haploidentical Transplant for Pe
 ople With Chronic Granulomatous Disease (CGD) Using Alemtuzumab\, Busulfan
  and TBI With Post-Transplant Cyclophosphamide\nEstimated primary completi
 on: 15 June 2034. This is a ClinicalTrials.gov estimate\, not a confirmed 
 readout date\, and it can move.\nDrug page: https://assetmemo.bio/drug/ale
 mtuzumab#upcoming-events\nRegistry record: https://clinicaltrials.gov/stud
 y/NCT03910452
URL:https://assetmemo.bio/drug/alemtuzumab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07616154-6149@assetmemo.bio
DTSTAMP:20261121T004952Z
DTSTART;VALUE=DATE:20340930
DTEND;VALUE=DATE:20341001
SUMMARY:Alemtuzumab: Phase 2 readout est. (NCT07616154)
DESCRIPTION:Alemtuzumab\, phase 2.\nStudy: Haploidentical Donor Hematopoiet
 ic Cell Transplant for Sickle Cell Disease\nEstimated primary completion: 
 September 2034. This is a ClinicalTrials.gov estimate\, not a confirmed re
 adout date\, and it can move.\nDrug page: https://assetmemo.bio/drug/alemt
 uzumab#upcoming-events\nRegistry record: https://clinicaltrials.gov/study/
 NCT07616154
URL:https://assetmemo.bio/drug/alemtuzumab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06851767-6149@assetmemo.bio
DTSTAMP:20261121T004952Z
DTSTART;VALUE=DATE:20341231
DTEND;VALUE=DATE:20350101
SUMMARY:Alemtuzumab: Phase 1/2 readout est. (NCT06851767)
DESCRIPTION:Alemtuzumab\, phase 1/2.\nStudy: Base-Edited Hematopoietic Stem
 /Progenitor Cell X-Linked Severe Combined Immunodeficiency Gene Therapy\nE
 stimated primary completion: 31 December 2034. This is a ClinicalTrials.go
 v estimate\, not a confirmed readout date\, and it can move.\nDrug page: h
 ttps://assetmemo.bio/drug/alemtuzumab#upcoming-events\nRegistry record: ht
 tps://clinicaltrials.gov/study/NCT06851767
URL:https://assetmemo.bio/drug/alemtuzumab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06358638-6149@assetmemo.bio
DTSTAMP:20261121T004952Z
DTSTART;VALUE=DATE:20440930
DTEND;VALUE=DATE:20441001
SUMMARY:Alemtuzumab: Phase 2 readout est. (NCT06358638)
DESCRIPTION:Alemtuzumab\, phase 2.\nStudy: Sickle Cell Disease Transplant U
 sing a Nonmyeloablative Approach for Patients With Anti-donor Red Cell Ant
 ibody\nEstimated primary completion: September 2044. This is a ClinicalTri
 als.gov estimate\, not a confirmed readout date\, and it can move.\nDrug p
 age: https://assetmemo.bio/drug/alemtuzumab#upcoming-events\nRegistry reco
 rd: https://clinicaltrials.gov/study/NCT06358638
URL:https://assetmemo.bio/drug/alemtuzumab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
END:VCALENDAR
